TY  - JOUR
AU  - Wankhede, Durgesh
AU  - Halama, Niels
AU  - Kloor, Matthias
AU  - Brenner, Hermann
AU  - Hoffmeister, Michael
TI  - Diabetes and Colorectal Cancer Risk and Survival According to Tumor Immunity Status.
JO  - Journal of clinical oncology
VL  - 43
IS  - 26
SN  - 0732-183X
CY  - Alexandria, Va.
PB  - American Society of Clinical Oncology
M1  - DKFZ-2025-01390
SP  - 2930-2941
PY  - 2025
N1  - #EA:C070#LA:C070# / 2025 Sep 10;43(26):2930-2941 / vormals D240
AB  - Type 2 diabetes (T2D) has been associated with an increased risk of colorectal cancer (CRC) and poorer survival outcomes. However, the role of tumor immune status in influencing these relationships remains unclear.We conducted a population-based matched case-control study (n = 4,724) with prospective long-term follow-up of CRC cases (n = 2,321; median follow-up, 9.5 years). Tumor immune status was assessed using an immune cell score (ICS), derived from CD3+ and CD8+ T-cell densities measured at the invasive margin and tumor core of resected specimens. ICS was stratified into high (ICSHi), intermediate (ICSInt), and low (ICSLow) immune infiltration on the basis of standard cutoffs (25
LB  - PUB:(DE-HGF)16
C6  - pmid:40658916
DO  - DOI:10.1200/JCO-25-00148
UR  - https://inrepo02.dkfz.de/record/302850
ER  -